SPRB vs. EGRX, CRVO, ACET, ADAG, IMUX, COYA, AFMD, PDSB, CYTT, and DMAC
Should you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Eagle Pharmaceuticals (EGRX), CervoMed (CRVO), Adicet Bio (ACET), Adagene (ADAG), Immunic (IMUX), Coya Therapeutics (COYA), Affimed (AFMD), PDS Biotechnology (PDSB), Cyteir Therapeutics (CYTT), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical preparations" industry.
Eagle Pharmaceuticals (NASDAQ:EGRX) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, community ranking, media sentiment, profitability, analyst recommendations, risk and valuation.
Eagle Pharmaceuticals received 374 more outperform votes than Spruce Biosciences when rated by MarketBeat users. Likewise, 70.31% of users gave Eagle Pharmaceuticals an outperform vote while only 62.30% of users gave Spruce Biosciences an outperform vote.
85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 9.1% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Spruce Biosciences had 3 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 6 mentions for Spruce Biosciences and 3 mentions for Eagle Pharmaceuticals. Spruce Biosciences' average media sentiment score of 0.20 beat Eagle Pharmaceuticals' score of 0.14 indicating that Eagle Pharmaceuticals is being referred to more favorably in the media.
Eagle Pharmaceuticals currently has a consensus price target of $17.00, suggesting a potential upside of 358.22%. Spruce Biosciences has a consensus price target of $5.67, suggesting a potential upside of 737.03%. Given Eagle Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Spruce Biosciences is more favorable than Eagle Pharmaceuticals.
Eagle Pharmaceuticals has higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Eagle Pharmaceuticals has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.49, indicating that its share price is 149% more volatile than the S&P 500.
Eagle Pharmaceuticals has a net margin of 0.00% compared to Eagle Pharmaceuticals' net margin of -461.67%. Spruce Biosciences' return on equity of 0.00% beat Eagle Pharmaceuticals' return on equity.
Summary
Eagle Pharmaceuticals beats Spruce Biosciences on 11 of the 18 factors compared between the two stocks.
Get Spruce Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spruce Biosciences Competitors List
Related Companies and Tools
